{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:00:22Z","timestamp":1791018022223,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T00:00:00Z","timestamp":1240185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:p>Xeroderma pigmentosum group D (XPD) participates in DNA unwinding during nucleotide excision repair, which may alter the efficacy of platinum\u2010based chemotherapy. We analyzed the influence of codon 751 Lys\u2192Gln polymorphism of <jats:italic>XPD<\/jats:italic> on its protein expression levels, clinico\u2010pathological features, and outcome of 188 Chinese patients with metastatic colorectal carcinoma (CRC) that had been treated with first\u2010line Oxaliplatin\u00a0+\u00a0Leucovorin\u00a0+\u00a05\u2010Fluorouracil (FOLFOX\u20104) chemotherapy. The results showed that in comparison with Caucasian populations, a remarkably lower prevalence of Lys\/Gln genotype was noted (16%, <jats:italic>n<\/jats:italic>\u00a0=\u00a030). No between\u2010group difference in XPD protein expression of patients with or without this polymorphism was noted (56.5%<jats:italic>vs<\/jats:italic> 59.7%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.783). Patients with Gln751 allele have a significantly lower response to FOLFOX\u20104 treatment (36.7%<jats:italic>vs<\/jats:italic> 58.2%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.03), and shorter progression\u2010free (7\u00a0<jats:italic>vs<\/jats:italic> 11\u00a0months; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01) and overall (14\u00a0<jats:italic>vs<\/jats:italic> 22\u00a0months; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01) survivals. The incidence of grade 3\/4 oxaliplatin\u2010neuropathies was very similar in both groups (13.3%<jats:italic>vs<\/jats:italic> 16.5%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.67). By adjusted analysis, this polymorphism was further identified as an independent prognostic factor (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.03). These data suggest that Asian populations have a significantly lower prevalence of codon 751 Lys\/Gln polymorphism in XPD, which could be a key determinant for good response to oxaliplatin\u2010based treatment and favorable outcomes. (<jats:italic>Cancer Sci<\/jats:italic> 2009; 100: 1261\u20131266)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01186.x","type":"journal-article","created":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T08:11:42Z","timestamp":1240215102000},"page":"1261-1266","source":"Crossref","is-referenced-by-count":31,"title":["Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX\u20104 treatment in Asian patients with colorectal carcinoma"],"prefix":"10.1111","volume":"100","author":[{"given":"Jiun\u2010I.","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng\u2010Hwai","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po\u2010Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen\u2010Kou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu\u2010Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2010Shone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng\u2010Kae","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huann\u2010Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2010Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_6_3_2","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond E","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.07.043"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0252"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0247"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","unstructured":"ChangMS TzengCH ChenPMet\u00a0al.ERCC1 codon 118 C>T polymorphism associated with ERCC1 expression and clinical outcome to FOLFOX\u20104 treatment in Asian patients with metastatic colorectal carcinoma.Cancer Sci2008Dec 4 (Epub ahead of print).","DOI":"10.1111\/j.1349-7006.2008.01031.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5539"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23361"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(96)90006-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/365852a0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0921-8777(93)90023-A"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06522.x"},{"key":"e_1_2_6_14_2","first-page":"8654","article-title":"Xeroderma pgmentosum group D gene polymorphism predicts clinical outcome to platinum\u2010based chemotherapy in patients with advanced colorectal cancer","volume":"61","author":"Park DJ","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3280115e63"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2007.02.010"},{"key":"e_1_2_6_17_2","first-page":"1354","article-title":"Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients","volume":"61","author":"Spitz MR","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.551"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1999.5833"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23370"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00541.x"},{"key":"e_1_2_6_22_2","first-page":"1091","article-title":"ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum\u2010based chemotherapy","volume":"32","author":"Kamikozuru H","year":"2008","journal-title":"Int J Oncol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601975"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-005-8170-3"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1247\/csf.20.191"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.12.1693"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M200008-MCP200"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.3.1720"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21885"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2161"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i37.6032"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01243894-200610000-00014"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.069"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0106"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2076"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2001.85.5.2293"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01186.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01186.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:12:18Z","timestamp":1697184738000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01186.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01186.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01186.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}